GSK 705498

Drug Profile

GSK 705498

Alternative Names: 705498; GSK-705498; SB-705498

Latest Information Update: 21 Jul 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Bromobenzenes; Non-opioid analgesics; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Atopic dermatitis; Cough; Dental pain; Migraine; Pain; Pruritus; Rhinitis

Most Recent Events

  • 31 Jul 2012 Phase-I clinical trials in Atopic dermatitis in United Kingdom (Topical)
  • 26 Jan 2012 GlaxoSmithKline completes a phase II trial in Cough in United Kingdom (NCT01476098)
  • 28 Sep 2011 Efficacy data from clinical trials in Rhinitis presented at the 21st Annual Congress of the European Respiratory Society (ERS-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top